Lung Cancer Drug Approval Tops SPT Week in Review


Top news of the week from Specialty Pharmacy Times.

5. New Opioid Prescribing Guidance Targets Inpatient Acute Pain Management

Until now, there has been little guidance on the safe prescribing of opioids in the inpatient, non-operative setting. Read more.

4. FDA Approves First-Line Treatment Combo for Advanced Renal Cell Carcinoma

Opdivo and Yervoy combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced RCC. Read more.

3. Inlyta Fails to Demonstrate Efficacy in Patients at High Risk of Recurrent Renal Cell Carcinoma

In its phase 3 trial, Pfizer’s axitinib (Inlyta) did not achieve disease-free survival in patients at high risk of recurrent renal cell carcinoma after nephrectomy. Read more.

2. Merck Announces Positive Phase 3 Results for Keytruda as Lung Cancer Therapy

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial. Read more.

1. FDA Approves Osimertinib for Treatment of Non-Small Cell Lung Cancer

Osimertinib surpassed standard of care with a median progression-free survival of 18.9 months in clinical trials. Read more.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская |
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages -
Image credit: alicja neumiler |
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Pharmacist preparing high-risk chemotherapy
Image Credit: © jarun011 -
© 2024 MJH Life Sciences

All rights reserved.